TACI monoallelic (heterozygous) or biallelic (homozygous or compound heterozygous) defects have been reported in 5–20% of patients with CVID and IgAD in several geographic areas globally [10,13,14,15]. This evidence concerns the gene TNFRSF13B and common variable immunodeficiency.